References

1.     Cescato, R., et al., Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med, 2006. 47(3): p. 502–11.

2.     Eychenne, R., et al., Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules, 2020. 25(17).

3.     Ginj, M., et al., Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A, 2006. 103(44): p. 16436–41.

4.     Wild, D., et al., First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med, 2011. 52(9): p. 1412–7.

5.     Wild, D., et al., Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med, 2014. 55(8): p. 1248–52.

6.     Nicolas, G.P., et al., Sensitivity Comparison of (68)Ga-OPS202 and (68)Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. J Nucl Med, 2018. 59(6): p. 915–921.

7.     Lin, Z., et al., Head-to-Head Comparison of (68)Ga-NODAGA-JR11 and (68)Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: Interim Analysis of a Prospective Bicenter Study. J Nucl Med, 2023. 64(9): p. 1406–1411.

8.     Reidy-Lagunes, D., et al., Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist (177)Lu-Satoreotide Tetraxetan. Clin Cancer Res, 2019. 25(23): p. 6939–6947.

9.     Wild, D., et al., A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 2023. 51(1): p. 183–195.

10.     Zhang, J., et al., First-in-human study of an optimized, potential kit-type, SSTR antagonist (68)Ga-DATA(5m)-LM4 in patients with metastatic neuroendocrine tumors. Theranostics, 2025. 15(6): p. 2510–2522.

11.     Liu, M., et al., Evaluation of the safety, biodistribution, dosimetry of [(18)F]AlF-NOTA-LM3 and head-to-head comparison with [(68)Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial. Eur J Nucl Med Mol Imaging, 2024. 51(12): p. 3719–3730.

12.     Baum, R.P., et al., First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med, 2021. 62(11): p. 1571–1581.

13.     Mapanao, A.K., et al., Preclinical investigation of [(149)Tb]Tb-DOTATATE and [(149)Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy. Eur J Nucl Med Mol Imaging, 2025. 52(4): p. 1383–1398.

14.     Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.

15.     Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.

16.     Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5950-6.

17.     Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.

18.     Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813-24.

19.     Yuan S, Almagro J, Fuchs E. Beyond genetics: driving cancer with the tumour microenvironment behind the wheel. Nat Rev Cancer. 2024;24(4):274-86.

20.     Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat Rev Cancer. 2025;25(1):41-58.

21.     Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238-50.

22.     Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. 2022;49(7):2323-41.

23.     Iravani A, Hicks RJ. Imaging the cancer immune environment and its response to pharmacological intervention- Part 2- The Role of Novel PET Agents. J Nucl Med. 2020.

24.     Iravani A, Hicks RJ. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of (18F)-FDG PET/CT. J Nucl Med. 2020;61(7):943-50.

25.     Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174-86.

26.     Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99-115.

27.     Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827-30.

28.     Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-208.

29.     Guelfi S, Hodivala-Dilke K, Bergers G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat Rev Cancer. 2024;24(10):655-75.

30.     Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-10.

31.     Suvac A, Ashton J, Bristow RG. Tumour hypoxia in driving genomic instability and tumour evolution. Nat Rev Cancer. 2025;25(3):167-88.

32.     Krzywinska E, Stockmann C. Hypoxia, Metabolism and Immune Cell Function. Biomedicines. 2018;6(2).

33.     Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

34.     Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-504.

35.     Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach. Nat Rev Clin Oncol. 2025;22(3):163-81.

36.     Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):402-21.

37.     Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018;52(Pt 2):39-52.

38.     Arpinati L, Carradori G, Scherz-Shouval R. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer. 2024;24(10):676-93.

39.     Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol. 2014;232(2):199-209.

40.     Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016;22(8):1865-74.

41.     Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2(10):735-47.

42.     Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84-91.

43.     Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11(8):2785-808.

44.     Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015;162(6):1229-41.

45.     Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, et al. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology. 2020;297(1):87-96.

46.     Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent. J Nucl Med. 2011;52(3):424-30.

47.     3Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF, Hollema H, et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010;51(5):761-7.

48.      Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17(5):985-91.10.1016/0360-3016(89)90146-6

49.     Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, et al. Tumour hypoxia imaging with [(18)F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging. 2007;34(10):1566-75.

50.     Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792-804.

51.     Mosessian S, Jensen JD, Enke AS. Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions. PET Clin. 2023;18(3):429-39.

52.     Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330-51.

53.     Hicks RJ, Giesel FL, Herrmann K. Fibroblast Activation Protein as a Diagnostic and Therapeutic Target: Where Do We Go from Here? PET Clin. 2023;18(3):xv-xx.

54.    Zang J, Lin R, Wen X, Wang C, Zhao T, Jakobsson V, et al. A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers. Clin Nucl Med. 2023;48(10):861-8.

55.     Nigam S, McCarl L, Kumar R, Edinger RS, Kurland BF, Anderson CJ, et al. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody. Mol Imaging Biol. 2020;22(3):685-94.

56.     Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, et al. First-in-Humans Imaging with  89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. J Nucl Med. 2020;61(4):512-9.

57.     Levi J, Goth S, Huynh L, Lam T, Huynh TL, Schulte B, et al. F-AraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy. J Nucl Med. 2021;62(6):802-7.

58.     Quan Z, Han Z, Yang Y, Wang J, Wang H, Yang L, et al. Noninvasive Monitoring of Immunotherapy in Lung Cancer by Lymphocyte Activation Gene 3 PET Imaging of Tumor-Infiltrating Lymphocytes. J Nucl Med. 2024;65(1):25-32.

59.     Ding L, Wang F, Wang Z, Pan Y, Liu T, Cheng L, et al. Construction of [89Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells. Mol Pharm. 2024;21(8):3992-4003.

60.     Zhou M, Chen B, Lu C, Yang J, Liu P, Wang X, et al. ImmunoPET imaging of LAG-3 expression in tumor microenvironment with 68Ga-labelled cyclic peptides tracers: from bench to bedside. J Immunother Cancer. 2024;12(7).

61.     Vincze SR, Jaswal AP, Frederico SC, Nisnboym M, Li B, Xiong Z, et al. ImmunoPET imaging of TIGIT in the glioma microenvironment. Sci Rep. 2024;14(1):5305.

62.     Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9(1):4664.

63.     Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, et al. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with. BMJ Open. 2022;12(11):e056708.

64.     Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, et al. Imaging immunity in patients with cancer using positron emission tomography. NPJ Precis Oncol. 2022;6(1):24.

65.     van Winkel CAJ, Pierik FR, Brouwers AH, de Groot DJA, de Vries EGE, Lub-de Hooge MN. Molecular imaging supports the development of multispecific cancer antibodies. Nat Rev Clin Oncol. 2024;21(12):852-66.

66.     Huisman MC, Niemeijer AN, Windhorst AD, Schuit RC, Leung D, Hayes W, et al. Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. J Nucl Med. 2020;61(10):1455-60.

67.     Donnelly DJ, Kim J, Tran T, Scola PM, Tenney D, Pena A, et al. The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. Eur J Nucl Med Mol Imaging. 2024;51(4):978-90.

68.     Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, et al. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Cent Sci. 2021;7(10):1638-49.

69.     Zhou H, Wang Y, Xu H, Shen X, Zhang T, Zhou X, et al. Noninvasive interrogation of CD8+ T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest. 2022;132(16).

70.     Gibson HM, McKnight BN, Malysa A, Dyson G, Wiesend WN, McCarthy CE, et al. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy. Cancer Res. 2018;78(19):5706-17.

71.     Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. Annu Rev Immunol. 2018;36:411-33.

72.     van de Donk PP, Wind TT, Hooiveld-Noeken JS, van der Veen EL, Glaudemans AWJM, Diepstra A, et al. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. Eur J Nucl Med Mol Imaging. 2021;48(13):4369-76.

73.     Glaudemans AWJM, Lammertsma AA, Cherry SR, Erba PA, Rominger A, Dierckx RAJO, et al. A cutting-edge technology for the future of nuclear medicine. Eur J Nucl Med Mol Imaging. 2025;52(3):791-5.